India  

Drugmaker Announces Promising Results of Potential Alzheimer's Treatment

Video Credit: Wibbitz Top Stories - Duration: 01:30s - Published
Drugmaker Announces Promising Results of Potential Alzheimer's Treatment

Drugmaker Announces Promising Results of Potential Alzheimer's Treatment

Drugmaker Announces , Promising Results of Potential , Alzheimer's Treatment.

On September 28, shares of Biogen and other drugmakers researching Alzheimer's disease skyrocketed after Japan's Eisai Co.

Announced promising late-stage study results.

'Time' reports that the company said its potential treatment appeared to slow the progress of the fatal disease.

On September 27, Eisai announced the results of a global study of nearly 1,800 people with early-stage Alzheimer's.

According to the drugmaker, early results show that the treatment reduced patients' decline by 27% over 18 months.

Eisai Co.

Also announced plans to discuss the trial's full results at a conference in November.

'Time' reports that the company plans to publish the findings in a peer-reviewed medical journal.

Meanwhile, the company has already sought accelerated approval from the U.S. Food and Drug Administration.

'Time' reports that the regulatory agency is expected to make a decision by early 2023.

The Alzheimer's Association released a statement calling the study's findings the most encouraging to date for potential treatments.

Following the announcement, shares of Biogen Inc.

Jumped over 50% in premarket trading to top $300


You Might Like


💡 newsR Knowledge: Other News Mentions

Food and Drug Administration Food and Drug Administration United States federal agency

The First Human Has Received Elon Musk’s Neuralink Brain Implant [Video]

The First Human Has Received Elon Musk’s Neuralink Brain Implant

The First Human Has Received , Elon Musk’s Neuralink Brain Implant. Musk took to X late on Jan. 29 to make the announcement, CNN reports. . The FDA cleared Neuralink for human clinical trials last year. The company recruited people with quadriplegia caused by either ALS or cervical spinal cord injury, CNN reports. . The trial is part of Neuralink's "PRIME Study," which stands for "Precise Robotically Implanted Brain-Computer Interface.". A robot installs the chip in the area of the brain responsible for the intention to move. . The chip then records brain signals and sends them to an app "to grant people the ability to control a computer cursor or keyboard using their thoughts alone," Neuralink said in September. Imagine if Stephen Hawking could communicate faster than a speed typist or auctioneer. That is the goal. , Elon Musk, via X. Other companies, such as Synchron, are also trying to develop brain-computer interfaces, CNN reports. . The idea of brain-nervous system interfaces has great potential to help people with neurological disorders in future. , Tara Spires-Jones, president of the British Neuroscience Association, via CNN. However, most of these interfaces require invasive neurosurgery and are still in experimental stages thus it will likely be many years before they are commonly available, Tara Spires-Jones, president of the British Neuroscience Association, via CNN

Credit: Wibbitz Top Stories    Duration: 01:31Published
Elon Musk's Neuralink implants brain chip in first human; ‘results promising’, says Musk | Oneindia [Video]

Elon Musk's Neuralink implants brain chip in first human; ‘results promising’, says Musk | Oneindia

The brain-chip startup Neuralink, founded by billionaire entrepreneur Elon Musk, achieved a major milestone over the weekend. The company successfully implanted its brain-computer interface (BCI) into the first human patient, marking a significant step forward in the field of neurotechnology. #Neuralink #ElonMusk #Telepathy #FDA #BrainChip #NeuralinkBrainChip ~PR.151~ED.101~

Credit: Oneindia    Duration: 02:43Published
Robitussin Products Recalled Nationwide [Video]

Robitussin Products Recalled Nationwide

Robitussin Products , Recalled Nationwide. Haleon, the manufacturer of Robitussin, is recalling the cough syrup because of a microbial contamination, 'The Hill' reports. . The recall was announced on Jan. 24. The products included in the recall are Robitussin Honey CF Max Day Adult and Robitussin Honey CF Max Adult. . According to Haleon, "the use of the affected product could potentially result in severe or life-threatening adverse events such as fungemia or disseminated fungal infection" in immunocompromised people. . In non-immunocompromised consumers, the population most likely to use the product, life-threatening infections are not likely to occur. , Haleon, Robitussin manufacturer, via statement. However, the occurrence of an infection that may necessitate medical intervention cannot be completely ruled out, Haleon, Robitussin manufacturer, via statement. Those in possession of these products are advised to halt consumption immediately. Haleon has also notified distributors, 'The Hill' reports. . If you've ingested the product and are experiencing problems, Haleon advises contacting your health care provider. The company also recommends reporting "adverse reactions or quality problems" to the FDA

Credit: Wibbitz Top Stories    Duration: 01:30Published
FDA Orders Drugmakers to Add Cancer Warning to CAR-T Treatments [Video]

FDA Orders Drugmakers to Add Cancer Warning to CAR-T Treatments

FDA Orders Drugmakers , to Add Cancer Warning to , CAR-T Treatments. This week, the Food and Drug Administration ordered drugmakers to add a warning to CAR-T cancer therapy, saying that the treatment may increase the risk of cancer. NBC reports that a spokesperson for the FDA said that despite the warning being ordered, , "the overall benefits of these products continue to outweigh their potential risks.". According to spokesperson Carly Kemper, the FDA's decision was prompted by reports of CAR-T patients developing rare forms of blood cancer. Kemper said that as of January 22, the agency had recorded 25 cases of CAR-T patients developing blood cancer. NBC reports that CAR-T, short for chimeric antigen receptor T cell, uses a patient's own immune cells to treat certain types of blood cancers. T cells are harvested, genetically altered to make them target cancer cells and then reinfused into the patient. . According to experts, the treatment has been highly effective in hard-to-treat cases. . This has been a game changer when we think about treating lymphoma and other diseases, Dr. Matthew Frigault, clinical director of the Massachusetts General Hospital Cellular Immunotherapy Program in Boston, via NBC. NBC reports that the first CAR-T therapy received FDA approval in 2017 with Novartis' drug, Kymriah. Another five drugs have since received FDA approval

Credit: Wibbitz Top Stories    Duration: 01:31Published